Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials

AIM: The aim of this study was to evaluate the effect of viloxazine extended-release capsules (viloxazine ER; Qelbree™) on executive function deficits (EFDs) in pediatric subjects (6–17 years of age) with attention-deficit/hyperactivity disorder (ADHD). METHODS: Data from four phase III placebo-cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Faraone, Stephen V., Gomeni, Roberto, Hull, Joseph T., Busse, Gregory D., Melyan, Zare, Rubin, Jonathan, Nasser, Azmi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563661/
https://www.ncbi.nlm.nih.gov/pubmed/34523063
http://dx.doi.org/10.1007/s40272-021-00470-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563661/
https://www.ncbi.nlm.nih.gov/pubmed/34523063
http://dx.doi.org/10.1007/s40272-021-00470-2

Ejemplares similares